Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Wednesday, 09'th Apr 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts
03:48pm, Wednesday, 02'nd Apr 2025
Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 25'th Mar 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
04:35pm, Wednesday, 26'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
07:01pm, Tuesday, 25'th Feb 2025
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago.
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Monday, 24'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Biotechs Highlight 6 Stocks Insiders Are Buying Now
08:45am, Sunday, 23'rd Feb 2025
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
06:52am, Tuesday, 18'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
03:45pm, Saturday, 15'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 11'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
05:00pm, Monday, 10'th Feb 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Friday, 24'th Jan 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025
10:51pm, Tuesday, 14'th Jan 2025
Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will repor
Arcus: Excellent Pipeline And Collaborations, Cash Runway
08:00am, Monday, 13'th Jan 2025
Arcus Biosciences presents a strong buying opportunity due to positive data, Gilead's increased stake, and a robust pipeline with significant market potential. Lead molecule domvanalimab shows promisi
